The 4G/5G Polymorphism of Plasminogen Activator Inhibitor Type 1 is a Predictor of Moderate-to-Severe Thyroid Eye Disease

References

• Terwee C, Wakelkamp I, Tan S, Dekker F, Prummel MF, Wiersinga W. Long-term effects of Graves’ ophthalmopathy on health-related quality of life. Eur J Endocrinol. 2002;146:751–757. doi:10.1530/eje.0.1460751
   PubMed Web of Science ®Google Scholar
• Kahaly GJ, Petrak F, Hardt J, Pitz S, Egle UT. Psychosocial morbidity of Graves’ orbitopathy. Clin Endocrinol (Oxf). 2005;63:395–402. doi:10.1111/j.1365-2265.2005.02352.x
   PubMed Web of Science ®Google Scholar
• Bartalena L, Baldeschi L, Boboridis K, et al.; (EUGOGO) EGoGO. The 2016 European Thyroid Association/European Group on Graves’ Orbitopathy Guidelines for the Management of Graves’ Orbitopathy. Eur Thyroid J. 2016;5:9–26. doi:10.1159/000443828
   PubMed Web of Science ®Google Scholar
• Stan MN, Bahn RS. Risk factors for development or deterioration of Graves’ ophthalmopathy. Thyroid. 2010;20:777–783. doi:10.1089/thy.2010.1634
   PubMed Web of Science ®Google Scholar
• Galgoczi E, Jeney F, Gazdag A, et al. Cell density-dependent stimulation of PAI-1 and hyaluronan synthesis by TGF-β in orbital fibroblasts. J Endocrinol. 2016;229:187–196. doi:10.1530/JOE-15-0524
   PubMed Web of Science ®Google Scholar
• Declerck PJ, Gils A. Three decades of research on plasminogen activator inhibitor-1: a multifaceted serpin. Semin Thromb Hemost. 2013;39:356–364. doi:10.1055/s-0033-1334487
   PubMed Web of Science ®Google Scholar
• Rabieian R, Boshtam M, Zareei M, Kouhpayeh S, Masoudifar A, Mirzaei H. Plasminogen activator inhibitor type-1 as a regulator of fibrosis. J Cell Biochem. 2018;119:17–27. doi:10.1002/jcb.26146
   PubMed Web of Science ®Google Scholar
• Milenkovic J, Milojkovic M, Jevtovic Stoimenov T, Djindjic B, Miljkovic E. Mechanisms of plasminogen activator inhibitor 1 action in stromal remodeling and related diseases. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2017;161:339–347. doi:10.5507/bp.2017.046
   PubMed Web of Science ®Google Scholar
• Longo CM, Higgins PJ. Molecular biomarkers of Graves’ ophthalmopathy. Exp Mol Pathol. 2019;106:1–6. doi:10.1016/j.yexmp.2018.11.004
   PubMed Web of Science ®Google Scholar
• Park YJ, Liu G, Lorne EF, et al. PAI-1 inhibits neutrophil efferocytosis. Proc Natl Acad Sci U S A. 2008;105:11784–11789. doi:10.1073/pnas.0801394105
   PubMed Web of Science ®Google Scholar
• Gupta KK, Xu Z, Castellino FJ, Ploplis VA. Plasminogen activator inhibitor-1 stimulates macrophage activation through toll-like receptor-4. Biochem Biophys Res Commun. 2016;477:503–508. doi:10.1016/j.bbrc.2016.06.065
   PubMed Web of Science ®Google Scholar
• Kawashima A, Yamazaki K, Hara T, et al. Demonstration of innate immune responses in the thyroid gland: potential to sense danger and a possible trigger for autoimmune reactions. Thyroid. 2013;23:477–487. doi:10.1089/thy.2011.0480
   PubMed Web of Science ®Google Scholar
• Erem C, Ersoz HO, Karti SS, et al. Blood coagulation and fibrinolysis in patients with hyperthyroidism. J Endocrinol Invest. 2002;25:345–350. doi:10.1007/BF03344016
   PubMed Web of Science ®Google Scholar
• Li Y, Chen H, Tan J, Wang X, Liang H, Sun X. Impaired release of tissue plasminogen activator from the endothelium in Graves’ disease - indicator of endothelial dysfunction and reduced fibrinolytic capacity. Eur J Clin Invest. 1998;28:1050–1054. doi:10.1046/j.1365-2362.1998.00381.x
   PubMed Web of Science ®Google Scholar
• Popławska-Kita A, Szelachowska M, Modzelewska A, et al. Endothelial dysfunction in Graves’ disease. Adv Med Sci. 2013;58:31–37. doi:10.2478/v10039-012-0047-1
   PubMed Web of Science ®Google Scholar
• Dawson SJ, Wiman B, Hamsten A, Green F, Humphries S, Henney AM. The two allele sequences of a common polymorphism in the promoter of the plasminogen activator inhibitor-1 (PAI-1) gene respond differently to interleukin-1 in HepG2 cells. J Biol Chem. 1993;268:10739–10745. doi:10.1016/S0021-9258(18)82047-6
   PubMed Web of Science ®Google Scholar
• Roncal C, Orbe J, Belzunce M, Rodríguez JA, Páramo JA. The 4G/5G PAI-1 polymorphism influences the endothelial response to IL-1 and the modulatory effect of pravastatin. J Thromb Haemost. 2006;4:1798–1803. doi:10.1111/j.1538-7836.2006.02031.x
   PubMed Web of Science ®Google Scholar
• Roncal C, Orbe J, Rodriguez JA, et al. Influence of the 4G/5G PAI-1 genotype on angiotensin II-stimulated human endothelial cells and in patients with hypertension. Cardiovasc Res. 2004;63:176–185. doi:10.1016/j.cardiores.2004.03.023
   PubMed Web of Science ®Google Scholar
• Eriksson P, Nilsson L, Karpe F, Hamsten A. Very-low-density lipoprotein response element in the promoter region of the human plasminogen activator inhibitor-1 gene implicated in the impaired fibrinolysis of hypertriglyceridemia. Arterioscler Thromb Vasc Biol. 1998;18:20–26. doi:10.1161/01.ATV.18.1.20
   PubMed Web of Science ®Google Scholar
• Ma Z, Jhun B, Jung SY, Oh CK. Binding of upstream stimulatory factor 1 to the E-box regulates the 4G/5G polymorphism-dependent plasminogen activator inhibitor 1 expression in mast cells. J Allergy Clin Immunol. 2008;121:1006–1012.e1002. doi:10.1016/j.jaci.2007.11.015
   PubMed Web of Science ®Google Scholar
• Prabhudesai A, Shetty S, Ghosh K, Kulkarni B. Investigation of plasminogen activator inhibitor-1 (PAI-1) 4G/5G promoter polymorphism in Indian venous thrombosis patients: a case-control study. Eur J Haematol. 2017;99:249–254. doi:10.1111/ejh.12912
   PubMed Web of Science ®Google Scholar
• Clarke GM, Anderson CA, Pettersson FH, Cardon LR, Morris AP, Zondervan KT. Basic statistical analysis in genetic case-control studies. Nat Protoc. 2011;6:121–133. doi:10.1038/nprot.2010.182
   PubMed Web of Science ®Google Scholar
• Draxler DF, Sashindranath M, Medcalf RL. Plasmin: a modulator of immune function. Semin Thromb Hemost. 2017;43:143–153. doi:10.1055/s-0036-1586227
   PubMed Web of Science ®Google Scholar
• Bae SC, Lee YH. Association between plasminogen activator inhibitor-1 (PAI-1) 4G/5G polymorphism and circulating PAI-1 level in systemic lupus erythematosus and rheumatoid arthritis: a meta-analysis. Z Rheumatol. 2020;79:312–318. doi:10.1007/s00393-019-00689-y
   PubMed Web of Science ®Google Scholar
• Anaya-Macias BU, De la Cruz-mosso U, Palafox-Sánchez CA, et al. The −675 4G/5G PAI-1 polymorphism confers genetic susceptibility to systemic lupus erythematosus, its clinical manifestations, and comorbidities in Mexican-Mestizo population. Autoimmunity. 2020;53:71–77. doi:10.1080/08916934.2019.1700957
   PubMed Web of Science ®Google Scholar
• Yousef AA, Mohamed FY, Boraey NF, et al. Association of plasminogen activator inhibitor 1 (PAI-1) 4G/5G polymorphism and susceptibility to SLE in Egyptian Children and Adolescents: a Multicenter Study. J Inflamm Res. 2020;13:1103–1111. doi:10.2147/JIR.S277373
   PubMed Web of Science ®Google Scholar
• Chen DP, Chu YC, Wen YH, Lin WT, Hour AL, Wang WT. Investigation of the correlation between Graves’ Ophthalmopathy and CTLA4 gene polymorphism. J Clin Med. 2019;8(11):1842. doi:10.3390/jcm8111842
   PubMed Web of Science ®Google Scholar
• Maciejewski A, Kowalczyk MJ, Gasińska T, et al. The role of vitamin D receptor gene polymorphisms in thyroid-associated orbitopathy. Ocul Immunol Inflamm. 2020;28:354–361. doi:10.1080/09273948.2019.1629605
   PubMed Web of Science ®Google Scholar
• Petunina NA, Martirosian NS, Trukhina LV, et al. Association between polymorphic markers in candidate genes and the risk of manifestation of endocrine ophthalmopathy in patients with Graves’ disease. Ter Arkh. 2018;90:35–39. doi:10.26442/terarkh2018901035-39
   PubMed Web of Science ®Google Scholar
• Shahida B, Planck T, Åsman P, Lantz M. Study of deiodinase type 2 polymorphisms in Graves’ disease and ophthalmopathy in a Swedish population. Eur Thyroid J. 2018;7:289–293. doi:10.1159/000490892
   PubMed Web of Science ®Google Scholar
• Di Paolo NC, Shayakhmetov DM. Interleukin 1α and the inflammatory process. Nat Immunol. 2016;17:906–913. doi:10.1038/ni.3503
   PubMed Web of Science ®Google Scholar
• Khalilzadeh O, Anvari M, Esteghamati A, et al. Graves’ ophthalmopathy and gene polymorphisms in interleukin-1alpha, interleukin-1beta, interleukin-1 receptor and interleukin-1 receptor antagonist. Clin Exp Ophthalmol. 2009;37:614–619. doi:10.1111/j.1442-9071.2009.02093.x
   PubMed Web of Science ®Google Scholar
• Laban-Guceva N, Bogoev M, Antova M. Serum concentrations of interleukin (IL-)1alpha, 1beta, 6 and tumor necrosis factor (TNF-) alpha in patients with thyroid eye disease (TED). Med Arh. 2007;61:203–206.
   PubMedGoogle Scholar
• Cao HJ, Wang HS, Zhang Y, Lin HY, Phipps RP, Smith TJ. Activation of human orbital fibroblasts through CD40 engagement results in a dramatic induction of hyaluronan synthesis and prostaglandin endoperoxide H synthase-2 expression. Insights into potential pathogenic mechanisms of thyroid-associated ophthalmopathy. J Biol Chem. 1998;273:29615–29625. doi:10.1074/jbc.273.45.29615
   PubMed Web of Science ®Google Scholar
• Mandić JJ, Kozmar A, Kusačić-Kuna S, et al. The levels of 12 cytokines and growth factors in tears: hyperthyreosis vs euthyreosis. Graefes Arch Clin Exp Ophthalmol. 2018;256:845–852. doi:10.1007/s00417-017-3892-6
   PubMed Web of Science ®Google Scholar
• Ujhelyi B, Gogolak P, Erdei A, et al. Graves’ orbitopathy results in profound changes in tear composition: a study of plasminogen activator inhibitor-1 and seven cytokines. Thyroid. 2012;22:407–414. doi:10.1089/thy.2011.0248
   PubMed Web of Science ®Google Scholar
• Kendler DL, Lippa J, Rootman J. The initial clinical characteristics of Graves’ orbitopathy vary with age and sex. Arch Ophthalmol. 1993;111:197–201. doi:10.1001/archopht.1993.01090020051022
   PubMedGoogle Scholar
• Smith LH, Coats SR, Qin H, et al. Differential and opposing regulation of PAI-1 promoter activity by estrogen receptor alpha and estrogen receptor beta in endothelial cells. Circ Res. 2004;95:269–275. doi:10.1161/01.RES.0000136521.70093.f1
   PubMed Web of Science ®Google Scholar
• Jin H, Lin J, Fu L, et al. Physiological testosterone stimulates tissue plasminogen activator and tissue factor pathway inhibitor and inhibits plasminogen activator inhibitor type 1 release in endothelial cells. Biochem Cell Biol. 2007;85:246–251. doi:10.1139/O07-011
   PubMed Web of Science ®Google Scholar
• Wiersinga WM. Smoking and thyroid. Clin Endocrinol (Oxf). 2013;79:145–151. doi:10.1111/cen.12222
   PubMed Web of Science ®Google Scholar
• Hu XY, Ma YH, Wang C, Yang YH. Effects of simvastatin on cigarette smoke extract induced tissue-type plasminogen activator and plasminogen activator inhibitor-1 expression in human umbilical vein endothelial cells. Chin Med J (Engl). 2009;122:2380–2385.
   PubMed Web of Science ®Google Scholar
• Xu X, Wang H, Wang Z, Xiao W. Plasminogen activator inhibitor-1 promotes inflammatory process induced by cigarette smoke extraction or lipopolysaccharides in alveolar epithelial cells. Exp Lung Res. 2009;35:795–805. doi:10.3109/01902140902912519
   PubMed Web of Science ®Google Scholar
• Jastrzebska M, Goracy I, Naruszewicz M. Relationships between fibrinogen, plasminogen activator inhibitor-1, and their gene polymorphisms in current smokers with essential hypertension. Thromb Res. 2003;110:339–344. doi:10.1016/j.thromres.2003.08.002
   PubMed Web of Science ®Google Scholar
• Bahn RS. Graves’ ophthalmopathy. N Engl J Med. 2010;362:726–738. doi:10.1056/NEJMra0905750
   PubMed Web of Science ®Google Scholar
• Laurberg P, Berman DC, Bülow Pedersen I, Andersen S, Carlé A. Incidence and clinical presentation of moderate to severe graves’ orbitopathy in a Danish population before and after iodine fortification of salt. J Clin Endocrinol Metab. 2012;97:2325–2332. doi:10.1210/jc.2012-1275
   PubMed Web of Science ®Google Scholar
• Loskutoff DJ, Sawdey M, Mimuro J. Type 1 plasminogen activator inhibitor. Prog Hemost Thromb. 1989;9:87–115.
   PubMedGoogle Scholar
• Chen CY, Chi LM, Chi HC, et al. Stable isotope labeling with amino acids in cell culture (SILAC)-based quantitative proteomics study of a thyroid hormone-regulated secretome in human hepatoma cells. Mol Cell Proteomics. 2012;11:M111.011270. doi:10.1074/mcp.M111.011270
   Web of Science ®Google Scholar
• Jackson-Hayes L, Song S, Lavrentyev EN, et al. A thyroid hormone response unit formed between the promoter and first intron of the carnitine palmitoyltransferase-Ialpha gene mediates the liver-specific induction by thyroid hormone. J Biol Chem. 2003;278:7964–7972. doi:10.1074/jbc.M211062200
   PubMed Web of Science ®Google Scholar